Yale researchers said that they anticipate their RNA extraction-free saliva assay will make testing more scalable, affordable, and available to the public.
Clinicians at Addenbrooke's Hospital in the UK are seeing reduced time to result and additional clinical benefits from using the DRW SAMBA II SARS-CoV-2 assay.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.
DNAe said its semiconductor-based platform has potential to detect a broader variety of pathogens and resistance genes than current molecular technologies.
The platform's portability and internet connectivity could enable it to locate and track the distribution of disease in real time, its developers said.
The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.
University of Oxford researchers said they are weeks away from completing clinical validation of a coronavirus molecular test based on RT-LAMP technology.
Hologic said laboratories may leverage the random-access and open-access capabilities of its Panther Fusion system to broaden screening for the novel coronavirus.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
